Literature DB >> 16091307

Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience.

John J Mitchell1, Bridget Wilcken, Ian Alexander, Carolyn Ellaway, Helen O'Grady, Veronica Wiley, John Earl, John Christodoulou.   

Abstract

Recent studies have shown that a subgroup of phenylketonuric patients respond to high doses of BH4 (20 mg/kg) by a decrease of plasma phenylalanine. A clinically significant response has been defined as a decrease in phenylalanine by more than 30% within 24 h, after a BH4 challenge. We report our experience with 37 patients diagnosed with hyperphenylalaninemia, mild, moderate, or classical Phenylketonuria (PKU) using a seven day combined BH4 and phenylalanine load. Nine of the 37 patients responded with a 30% decrease in their phenylalanine levels in the first 8 h of treatment. A total of 17 patients (46%) had a decrease of at least 30% during the study period. This study confirms that a significant number of patients with mild to moderate PKU will respond to a BH4 load. Furthermore, it confirms that the seven-day phenylalanine test is more sensitive in detecting BH4 responsive patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091307     DOI: 10.1016/j.ymgme.2005.06.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Authors:  Rani H Singh; Meghan E Quirk
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

Review 2.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

3.  Prevalence of tetrahydrobiopterine (BH4)-responsive alleles among Austrian patients with PAH deficiency: comprehensive results from molecular analysis in 147 patients.

Authors:  Elisabeth Sterl; Karl Paul; Eduard Paschke; Johannes Zschocke; Michaela Brunner-Krainz; Eva Windisch; Vassiliki Konstantopoulou; Dorothea Möslinger; Daniela Karall; Sabine Scholl-Bürgi; Wolfgang Sperl; Florian Lagler; Barbara Plecko
Journal:  J Inherit Metab Dis       Date:  2012-04-25       Impact factor: 4.982

4.  Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency.

Authors:  M R Zurflüh; L Fiori; B Fiege; I Ozen; M Demirkol; K H Gärtner; B Thöny; M Giovannini; N Blau
Journal:  J Inherit Metab Dis       Date:  2006-11-07       Impact factor: 4.982

Review 5.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

6.  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.

Authors:  Cary O Harding
Journal:  Biologics       Date:  2010-08-09

7.  The Molecular Bases of Phenylketonuria (PKU) in New South Wales, Australia: Mutation Profile and Correlation with Tetrahydrobiopterin (BH4) Responsiveness.

Authors:  Gladys Ho; Ian Alexander; Kaustuv Bhattacharya; Barbara Dennison; Carolyn Ellaway; Sue Thompson; Bridget Wilcken; John Christodoulou
Journal:  JIMD Rep       Date:  2013-12-25

8.  Effect of BH(4) supplementation on phenylalanine tolerance.

Authors:  A Burlina; N Blau
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

Review 9.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

10.  Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype.

Authors:  Karen Anjema; Margreet van Rijn; Floris C Hofstede; Annet M Bosch; Carla E M Hollak; Estela Rubio-Gozalbo; Maaike C de Vries; Mirian C H Janssen; Carolien C A Boelen; Johannes G M Burgerhof; Nenad Blau; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2013-07-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.